Skip to Content
Merck
All Photos(2)

Documents

SML3697

Sigma-Aldrich

Anagliptin

≥98% (HPLC)

Synonym(s):

(S)-N-(2-(2-(2-Cyanopyrrolidin-1-yl)-2-oxoethylamino)-2-methylpropyl)-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide, N-[2-({2-[(2S)-2-Cyanopyrrolidine-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide, SK 0403, SK-0403, SK0403

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C19H25N7O2
CAS Number:
739366-20-2
Molecular Weight:
383.45
MDL number:
MFCD19443729
UNSPSC Code:
51111800
UNSPSC Code:
12352200
NACRES:
NA.21

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Anagliptin is an orally active, potent and selective dipeptidyl peptidase 4 (DPP-IV; DPP4) inhibitor (DPP4/8/9 IC50 = 3.8/68/60 nM). When administered in vivo (0.3% w/w in diet), anagliptin shows anti-atherosclerotic efficay in apoE-deficient mice and ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Noriyasu Kato et al.
Bioorganic & medicinal chemistry, 19(23), 7221-7227 (2011-10-25)
In the course of our program for discovery of novel DPP-IV inhibitors, a series of pyrazolo[1,5-a]pyrimidines were found to be novel DPP-IV inhibitors. We identified N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (4a) and described its pharmacological profiles.
Keizo Nakaya et al.
Metabolism: clinical and experimental, 62(7), 939-951 (2013-06-26)
Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia with insulin resistance and impaired insulin secretion. DPP-4 inhibitors have attracted attention as a new class of anti-diabetic agents for the treatment of type 2 diabetes. We investigated the
Nasib Ervinna et al.
Endocrinology, 154(3), 1260-1270 (2013-01-23)
Dipeptyl peptidase-4 (DPP-4) inhibitors modulate the progression of atherosclerosis. To gain insights into their mechanism of action, 9-wk-old male apolipoprotein E (apoE)-deficient mice were fed a DPP-4 inhibitor, anagliptin-containing diet. The effects of anagliptin were investigated in, a monocyte cell

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service